ALF President & CEO Transitions to New Role
This last month is one without precedent. Our world as we know it has changed dramatically as a result of the global COVID-19 coronavirus pandemic. Tragically, the momentum generated by the American Liver Foundation has been severely impacted by our need to cancel or postpone our many fundraising events. Our organization’s dedicated volunteers and staff leaders are making difficult choices due to our current reality. Nonprofit leaders throughout the country are consolidating and restructuring for the benefit of their individual missions. The American Liver Foundation is no exception.
Our President and CEO, Thomas Nealon III will be stepping down from his current position effective April 1, 2020 and become a volunteer. Tom will continue to serve as a highly-valued member of our national board and also as a special advisor to the chair. I am very pleased that Tom will serve in his new role as a volunteer and advisor as we navigate the challenging course ahead of us. The day-to-day management of the ALF will continue under the able leadership of Lynn Seim, Executive Vice President & Chief Operating Officer and David Ticker, Executive Vice President & Chief Financial Officer.
For two decades, Tom Nealon has been a compassionate and visionary volunteer and then leader of the American Liver Foundation. From the time he ran his first Boston Marathon in support of a young child with Biliary Atresia – raising millions for our important cause, to the last seven years when he served first as national board chair and then as President and CEO, Tom has provided meritorious leadership benefiting millions of liver patients and their family members.
Under Tom’s leadership, significant progress has been made in raising overall awareness of liver disease. The American Liver Foundation has expanded its public education programs for both medical professionals and patient families, created national and local medical advisory committees, expanded our federal advocacy efforts, secured new organizational and industry partnerships, provided critical support to young researchers, shared the patient voice at national conferences and provided lifesaving information and services to an unprecedented number of individuals with liver disease as well as their families, friends and those at risk.
Tom has been a tremendous champion for the American Liver Foundation across the country, both attending and financially supporting hundreds of division events. He has served as chief media spokesperson for the organization, both amplifying the voice of the liver patient, promoting optimal liver health and reducing the stigma of liver disease.
Having attended law school in our nation’s capital, Tom is an effective and passionate advocate for the liver community in the halls of Congress and with the FDA. Four years ago, Tom was appointed by the U.S. Secretary of Health & Human Services to be the liver disease public representative on the NIH’s National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Advisory Council, serving our community with distinction.
I am also very grateful for Tom’s leadership during a prior crisis nearly a decade ago. At that time, Tom stepped up to help the American Liver Foundation through a difficult organizational challenge, guiding a reorganization to ensure sustainable growth. Due to the global pandemic we face today, Tom is once again enabling the organization to respond effectively to achieve its mission.
I ask you to join me in acknowledging Tom’s unprecedented legacy of service at the American Liver Foundation and thank him for his great compassion and tireless effort.
Tom, on behalf of everyone associated with the American Liver Foundation, thank you and we look forward to continuing to have you as a colleague in your new role. Our world is a better place because of you.
With great appreciation,
Chair, National Board of Directors
American Liver Foundation
Share this page